Hopkins and Dana-Farber researchers report that immune system-based therapy produces lasting remissions in melanoma patients
Nivolumab, a drug that unleashes the immune system to attack cancer, is now shown to produce lasting remissions and hold the disease in check — for more than two years, in some cases — in many patients with advanced melanoma, according to a new study by researchers from Dana-Farber Cancer Institute and Johns Hopkins Medicine.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.